OMER - Why Omeros Corporation (OMER) Shares Are Nosediving | Benzinga
Omeros Corp (NASDAQ: OMER) shares are trading lower by 47% to $1.20 during Monday's pre-market session. The company has provided an update on its Phase 3 trial (ARTEMIS-IGAN) evaluating narsoplimab for the treatment of IgA nephropathy, an immunologic disorder.
What Happened?
The trial aimed to reduce proteinuria in IgA nephropathy ...
OMER) Shares Are Nosediving>Full story available on Benzinga.com